News from Friday, October 3, 2025
Articles
Value Viewpoint: October 3, 2025
(10/3, Kimberly Westrich, LinkedIn) comments “The American Heart Association (AHA) and American College of Cardiology (ACC) recently released the 2025 AHA/ACC Statement on Cost/Value Methodology in Clinical Practice Guidelines, updating the 2014 Statement. While I rarely use AI in my work, I thought it might be interesting to let ChatGPT summarize the differences for us (we confirmed that nothing was garbled or misstated): ‘In summary, the 2025 statement builds upon the 2014 foundation by refining the methodology, updating key thresholds, and expanding the scope to explicitly address health equity and patient-centered financial considerations, providing a more comprehensive framework for integrating economic value into clinical practice guidelines.’” Full
Can AI Help Deliver CMS’s Value-Based Care Agenda?
(10/3, Michael S. Barr, Health Affairs Forefront) comments “...I posit that the success of value-based Care (VBC) programs, including the assumption of more risk, can be accelerated with optimized artificial intelligence (AI) to support clinical workflows and quality gap closures. I first explore VBC programs and downside risk and then present two reasons why VBC programs are not achieving the desired results. I then make the case that, absent appropriate use of AI, the push for more downside risk under VBC programs, coupled with the transition to digital quality measures (dQMs) and the elimination of the hybrid method of calculating performance, could overwhelm health care professionals already overtasked and suffering from burnout.” Full
Most Drug Firms Fail To Comply With Key EU HTA Step, EMA Warns
(10/3, Eliza Slawther, Pink Sheet) reports “...More than half of drug marketing authorization applicants whose products fell within the scope of the Health Technology Assessment Regulation this year failed to communicate with the HTA Secretariat as required, a senior figure at the European Medicines Agency says.” Subscription Required
Press Releases
New Results from Long-Term Study Show Early Use of Biologics Improves Outcomes for Children with Polyarticular Juvenile Idiopathic Arthritis
(10/3, Childhood Arthritis and Rheumatology Research Alliance Press Release) “...After following nearly 300 children with poly JIA in the CARRA Registry for three years, researchers discovered that patients who started the Early Combination CTP (biologics and methotrexate together) have better outcomes and spent more time in inactive disease than those who received the Step-Up CTP, which starts with methotrexate alone and adds a biologic later if needed. A separate analysis of the study found that patients who start biologics very early (by two months) have the best disease trajectory. The results were recently published in Arthritis & Rheumatology.” Full
Journals
Three-Year Outcomes and Latent Class Trajectory Analysis of the Childhood Arthritis and Rheumatology Research Alliance Polyarticular JIA Consensus Treatment Plans Study
Sarah Ringold, et al.
October 2025, Arthritis & Rheumatology
Acute Surgery vs Conservative Treatment for Traumatic Acute Subdural Hematoma
Thomas A Van Essen, et al.
October 1, 2025, JAMA Network Open
Comparative Effectiveness of Titanium Platelet-Rich Fibrin and Connective Tissue Graft Harvested from the Tuberosity Area Via Modified Vestibular Incision Supraperiosteal Tunnel Access for Managing Gingival Recession: Protocol for a Randomized Controlled Trial
Sanehi Punse, Prasad Dhadse
October 2, 2025, JMIR Research Protocols
Head-to-Head in Heart Failure: Comparative Insights on Empagliflozin and Dapagliflozin
Dragos Cozma, et al.
October 3, 2025, biomedicines